ABCL Stock Overview
AbCellera Biologics Inc. develops antibody discovery platform.
AbCellera Biologics Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$10.65|
|52 Week High||US$22.63|
|52 Week Low||US$5.42|
|1 Month Change||42.00%|
|3 Month Change||11.64%|
|1 Year Change||-48.65%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-81.92%|
Recent News & Updates
AbCellera Biologics: Fully Funded, With New Opportunities And Massive Insider Buying
AbCellera stock has continued to struggle of late given the absolutely terrible sentiment in the biotech market, however the company's actual business is thriving under the surface. In the Q1 earnings call, the company highlighted both the internally developed T-Cell engager platform, along with the Empirico deal which provides the option to co-invest in programs. The company is currently sitting on a mountain of cash, $786 million worth and this balance looks to grow further with $334 million in accrued receivables from bebtelovimab. Insiders clearly appreciate the opportunity ahead as the CEO, CFO & COO each purchased significant amounts of stock directly after the Q1 release and insiders now own over 27% of the business.
Need To Know: Analysts Are Much More Bullish On AbCellera Biologics Inc. (NASDAQ:ABCL)
AbCellera Biologics Inc. ( NASDAQ:ABCL ) shareholders will have a reason to smile today, with the analysts making...
|ABCL||US Life Sciences||US Market|
Return vs Industry: ABCL underperformed the US Life Sciences industry which returned -15.9% over the past year.
Return vs Market: ABCL underperformed the US Market which returned -18.4% over the past year.
|ABCL Average Weekly Movement||11.3%|
|Life Sciences Industry Average Movement||11.4%|
|Market Average Movement||8.1%|
|10% most volatile stocks in US Market||16.6%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: ABCL is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: ABCL's weekly volatility (11%) has been stable over the past year.
About the Company
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners.
AbCellera Biologics Fundamentals Summary
|ABCL fundamental statistics|
Is ABCL overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ABCL income statement (TTM)|
|Cost of Revenue||US$146.22m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||0.72|
|Net Profit Margin||41.88%|
How did ABCL perform over the long term?See historical performance and comparison
Is ABCL undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ABCL?
Other financial metrics that can be useful for relative valuation.
|What is ABCL's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does ABCL's PE Ratio compare to its peers?
|ABCL PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
Price-To-Earnings vs Peers: ABCL is good value based on its Price-To-Earnings Ratio (14.8x) compared to the peer average (29.3x).
Price to Earnings Ratio vs Industry
How does ABCL's PE Ratio compare vs other companies in the U.S. Life Sciences Industry?
Price-To-Earnings vs Industry: ABCL is good value based on its Price-To-Earnings Ratio (14.8x) compared to the US Life Sciences industry average (30.5x)
Price to Earnings Ratio vs Fair Ratio
What is ABCL's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||14.8x|
|Fair PE Ratio||11.9x|
Price-To-Earnings vs Fair Ratio: ABCL is expensive based on its Price-To-Earnings Ratio (14.8x) compared to the estimated Fair Price-To-Earnings Ratio (11.9x).
Share Price vs Fair Value
What is the Fair Price of ABCL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate ABCL's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate ABCL's fair value for valuation analysis.
Price to Earnings Growth Ratio
PEG Ratio: ABCL's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Discover undervalued companies
How is AbCellera Biologics forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ABCL's earnings are forecast to decline over the next 3 years (-52.3% per year).
Earnings vs Market: ABCL's earnings are forecast to decline over the next 3 years (-52.3% per year).
High Growth Earnings: ABCL's earnings are forecast to decline over the next 3 years.
Revenue vs Market: ABCL's revenue is expected to decline over the next 3 years (-38.9% per year).
High Growth Revenue: ABCL's revenue is forecast to decline over the next 3 years (-38.9% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ABCL's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has AbCellera Biologics performed over the past 5 years?
Past Performance Score2/6
Past Performance Score 2/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ABCL has high quality earnings.
Growing Profit Margin: ABCL's current net profit margins (41.9%) are lower than last year (47.1%).
Past Earnings Growth Analysis
Earnings Trend: ABCL's earnings have grown significantly by 88.3% per year over the past 5 years.
Accelerating Growth: ABCL's earnings growth over the past year (0.8%) is below its 5-year average (88.3% per year).
Earnings vs Industry: ABCL earnings growth over the past year (0.8%) underperformed the Life Sciences industry 21%.
Return on Equity
High ROE: ABCL's Return on Equity (17%) is considered low.
Discover strong past performing companies
How is AbCellera Biologics's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: ABCL's short term assets ($1.2B) exceed its short term liabilities ($213.4M).
Long Term Liabilities: ABCL's short term assets ($1.2B) exceed its long term liabilities ($171.4M).
Debt to Equity History and Analysis
Debt Level: ABCL is debt free.
Reducing Debt: ABCL had no debt 5 years ago.
Debt Coverage: ABCL has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: ABCL has no debt, therefore coverage of interest payments is not a concern.
Discover healthy companies
What is AbCellera Biologics's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ABCL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ABCL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ABCL's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ABCL's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ABCL has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Carl Hansen (46 yo)
Dr. Carl L. G. Hansen, Ph.D. is a Co-Founder of AbCellera Biologics Inc. and has been its Chief Executive Officer and Director since November 2012 and serves as its Chairperson. Dr. Hansen serves as a Memb...
CEO Compensation Analysis
Compensation vs Market: Carl's total compensation ($USD9.12M) is above average for companies of similar size in the US market ($USD6.88M).
Compensation vs Earnings: Carl's compensation has been consistent with company performance over the past year.
Experienced Management: ABCL's management team is considered experienced (2.8 years average tenure).
Experienced Board: ABCL's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: ABCL insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5%.
AbCellera Biologics Inc.'s employee growth, exchange listings and data sources
- Name: AbCellera Biologics Inc.
- Ticker: ABCL
- Exchange: NasdaqGS
- Founded: 2012
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$3.030b
- Shares outstanding: 284.54m
- Website: https://www.abcellera.com
Number of Employees
- AbCellera Biologics Inc.
- 2215 Yukon Street
- British Columbia
- V5Y 0A1
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/26 00:00|
|End of Day Share Price||2022/06/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.